Skip to content

Jazz Pharmaceuticals JAZZ Reclassification From Aoci Current Period Net Of Tax Attributable To Parent

Reclassification From Aoci Current Period Net Of Tax Attributable To Parent at other companies

Jefferies Financial Group logo
Jefferies Financial GroupJEF
$0
Baxter International logo
Baxter InternationalBAX
$0+100%
Corebridge Financial logo
Corebridge FinancialCRBG
Two Harbors Investment Corporation logo
Two Harbors Investment CorporationTWO
Corebridge Financial logo
Corebridge FinancialCRBG
Two Harbors Investment Corporation logo
Two Harbors Investment CorporationTWO

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's reclassification from aoci current period net of tax attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's reclassification from aoci current period net of tax attributable to parent?
Jazz Pharmaceuticals (JAZZ) reported reclassification from aoci current period net of tax attributable to parent of -$200K in Q1 2026.
How has Jazz Pharmaceuticals's reclassification from aoci current period net of tax attributable to parent changed year-over-year?
Jazz Pharmaceuticals's reclassification from aoci current period net of tax attributable to parent decreased by 150.5% year-over-year, from $396K to -$200K.
What is the long-term trend for Jazz Pharmaceuticals's reclassification from aoci current period net of tax attributable to parent?
Over 2 years (2021 to 2025), Jazz Pharmaceuticals's reclassification from aoci current period net of tax attributable to parent has grown at a -30.7% compound annual growth rate (CAGR), from -$2.73M to $1.31M.
What does reclassification from aoci current period net of tax attributable to parent mean?
The portion of previously unrealized gains or losses that are now being recognized in the current period's net income.
How do you interpret reclassification from aoci current period net of tax attributable to parent?
Reclassifications represent the realization of past economic events, impacting current period earnings volatility.
How does reclassification from aoci current period net of tax attributable to parent compare across companies?
Common in companies with active hedging programs or significant investment portfolios.